Immutep Limited

NASDAQ:IMMP

Biotechnology

Healthcare
$0.37 +0.64%

+$0.00 today

Market cap
$55.01M
Beta
2.24
P/E (TTM)
-0.9
EPS (TTM)
-$0.06
52W Low $0.29High $3.53

Volume 3.10M

Average 13.46M

IMMP Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Immutep LimitedNASDAQ: IMMP

Cash & Equivalents · Q2 FY2026 · quarter ended Dec 2025

Cash & equivalents broadly unchanged from a year ago

Cash & equivalents stood at A$72.75M at the end of Q2 FY2026, down 1.5% from a year earlier. Over 3 fiscal years it compounded at -5.5% a year.

Context

  • Cash & equivalents amounted to 49.4% of total assets at the end of Q2 FY2026, up 8.9 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -1.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
A$72.75M— QoQ
Last fiscal yearJun 2025
A$67.41M-58.3% YoY
Year agoDec 2024
A$73.89M-1.5% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.5%——
1 year-58.3%——
3-year CAGR-5.5%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

AUD · from the balance sheet

Latest · FY2025
67.41M AUD
Year-over-year change
-58.3%
4-year CAGR
+2.9%

Cash & Equivalents vs competitors

How IMMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -1.5% is the 5th highest of 11, against a peer median of -11.2%.
  • Cash & equivalents amounts to 49.4% of total assets for IMMP, versus a peer median of 80.3%.
IMMP Competitors
Cash & Equivalents for IMMP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CADLCandel Therapeutics, Inc.Mar 2026$194.83M USD+111.4%+19.6%96.5%
EDITEditas Medicine, Inc.Mar 2026$123.65M USD-10.8%+1.2%82.8%
CABACabaletta Bio, Inc.Mar 2026$116.64M USD-11.5%+0.6%78.7%
CAPRCapricor Therapeutics, Inc.Mar 2026$105.42M USD+266.1%+210.6%32.3%
PRQRProQR Therapeutics N.V.Mar 2026€81.17M EUR-43.2%-0.9%81.9%
TRDAEntrada Therapeutics, Inc.Mar 2026$76.44M USD+12.7%+26.0%22.8%
IMMPImmutep LimitedDec 2025A$72.75M AUD-1.5%-5.5%49.4%
VNDAVanda Pharmaceuticals Inc.Mar 2026$54.03M USD-51.7%-14.3%12.5%
MREOMereo BioPharma Group plcMar 2026$36.22M USD-42.0%-15.6%89.2%
ALLOAllogene Therapeutics, Inc.Mar 2026$30.31M USD-28.6%-5.8%7.7%
ACHVAchieve Life Sciences, Inc.Mar 2026$28.08M USD+115.7%-5.4%84.8%
Peer median (excluding IMMP) —-11.2%-0.1%80.3%

Competitors are the stored peer set for IMMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Cash & Equivalents60.13M80M123.42M161.79M67.41M
Short-term Investments00020.09M62.28M
Net Receivables6.12M8.37M7.97M7.56M7.46K
Inventory(5.66M)0000
Other Current Assets6.16M00010.87M
Total Current Assets68.42M90.81M134.97M191.35M149.1M
Property, Plant & Equipment (Net)309.7K308.08K468.51K679.72K569.48K
Goodwill109.96K109.96K109.96K109.96K109.96K
Intangible Assets12.74M10.44M9.38M8.13M7.09M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets454.19K495.66K2.52M1.31M116.64K
Total Non-current Assets13.61M11.36M12.48M10.23M7.89M
Total Assets82.03M102.17M147.45M201.58M156.98M
Account Payables1.82M2.87M5.45M3.79M5.53M
Short-term Debt208.19K0001.1M
Tax Payables0(32.21M)000
Deferred Revenue00000
Other Current Liabilities2.75M3.02M354.84K428.71K446.95K
Total Current Liabilities5.34M6.41M9.77M10.49M12.76M
Long-term Debt2.53M1.45M835.45K960.76K0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities811.88K117.25K164.43K211.02K274.31K
Total Non-current Liabilities3.42M1.68M1.21M1.57M589.23K
Total Liabilities8.76M8.09M10.98M12.06M13.35M
Common Stock313.42M367.41M446.27M542.11M535.07M
Retained Earnings(274.64M)(302.34M)(339.93M)(382.65M)(444.08M)
Accumulated OCI34.49M29M30.13M30.06M52.65M
Other Stockholders Equity00000
Minority Interest00000
Total Equity73.27M94.08M136.47M189.52M143.64M
Total Debt2.82M1.73M1.23M1.59M1.63M
Net Debt(57.31M)(78.26M)(122.19M)(160.2M)(65.78M)

Immutep Limited

NASDAQ:IMMP

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.